2024
Achieving Adherence With NCCN Guidelines for Nonmelanoma Skin Cancer Regarding Peripheral and Deep En Face Margin Assessment (PDEMA).
Xu Y, Lim Y, Bordeaux J, Aasi S, Alam M, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Grekin R, Mark L, Nehal K, Nghiem P, Olino K, Patel T, Scott J, Shaha A, Srivastava D, Schmults C. Achieving Adherence With NCCN Guidelines for Nonmelanoma Skin Cancer Regarding Peripheral and Deep En Face Margin Assessment (PDEMA). Journal Of The National Comprehensive Cancer Network 2024, 22 PMID: 39536442, DOI: 10.6004/jnccn.2024.7037.Peer-Reviewed Original ResearchConceptsMargin assessmentCell carcinomaNCCN guidelinesHigh-risk basal cell carcinomasCutaneous squamous cell carcinomaDeep margin assessmentMohs micrographic surgerySquamous cell carcinomaBasal cell carcinomaNonmelanoma skin cancerMicrographic surgeryDermatofibrosarcoma protuberansCure rateOptimal patient outcomesUninvolved tissueAccurate resectionSkin cancerPatient outcomesNCCNCarcinomaHistological visualizationMarginal surfacesTissueCCPDMAResection681 - Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate-to-severe atopic dermatitis in the United States: a population-based study using claims data
Vleugels R, Grada A, Yue E, Bunick C, Galimberti F, Krueger W. 681 - Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate-to-severe atopic dermatitis in the United States: a population-based study using claims data. British Journal Of Dermatology 2024, 191: ljae266.055. DOI: 10.1093/bjd/ljae266.055.Peer-Reviewed Original ResearchNon-melanoma skin cancerRisk of malignancyModerate-to-severe diseaseCohort entry dateAtopic dermatitisRheumatoid arthritisFollow-upModerate-to-severe atopic dermatitisSkin cancerNon-AD cohortIncidence of malignancyNonmelanoma skin cancerSubgroup of patientsNon-AD controlsFollow-up periodCox proportional hazards modelsChronic liver diseaseEffect of disease activityInternational Classification of Diseases (ICD)-9Population-based studyProportional hazards modelClinformatics Data MartSystemic therapyClaims-based studyOptum Clinformatics Data Mart
2023
Rare tumors: Opportunities and challenges from the Children’s Oncology Group perspective
Schultz K, Chintagumpala M, Piao J, Chen K, Shah R, Gartrell R, Christison-Lagay E, Pashnakar F, Berry J, O'Neill A, Vasta L, Flynn A, Mitchell S, Seynnaeve B, Rosenblum J, Potter S, Kamihara J, Rodriguez-Galindo C, Hawkins D, Laetsch T. Rare tumors: Opportunities and challenges from the Children’s Oncology Group perspective. 2023, 2: 100024. PMID: 37829670, PMCID: PMC10566015, DOI: 10.1016/j.ejcped.2023.100024.Peer-Reviewed Original ResearchTumor CommitteeStromal tumorsDesmoplastic small round cell tumorSmall round cell tumorGastrointestinal stromal tumorsNonmelanoma skin cancerRound cell tumorGonadal stromal tumorPleuropulmonary blastomaRare tumorAdrenocortical carcinomaNeuroendocrine tumorsCell tumorsRare cancersChildhood cancerColorectal carcinomaPancreatic tumorsNasopharyngeal carcinomaThyroid carcinomaHigh-quality researchCarcinomaSkin cancerTumorsYoung adultsCancer427 Long-term 4-year safety of upadacitinib in moderate-to-severe atopic dermatitis: results of an integrated analysis of phase 3 studies
Silverberg J, Bunick C, Lio P, Guttman-Yassky E, Boguniewicz M, Blauvelt A, Bieber T, Thyssen J, Suravaram S, Khan N, Dilley D, Teixeira H, Vigna N, Gamelli A, Grada A, Irvine A. 427 Long-term 4-year safety of upadacitinib in moderate-to-severe atopic dermatitis: results of an integrated analysis of phase 3 studies. British Journal Of Dermatology 2023, 188: ljad162.047. DOI: 10.1093/bjd/ljad162.047.Peer-Reviewed Original ResearchAbstract Atopic dermatitisNonmelanoma skin cancerMajor adverse cardiovascular eventsVenous thromboembolic eventsPhase 3 studyUpadacitinib 15Adverse eventsAtopic dermatitisSerious infectionsAdjudicated major adverse cardiovascular eventOral Janus kinase 1 inhibitorTreatment-emergent adverse eventsLong-term safety dataFavorable benefit-risk profilePivotal phase 3 studiesConcomitant topical corticosteroidsDouble-blinded periodEczematous skin lesionsEfficacy of upadacitinibPivotal phase 3Rapid itch reliefAdverse cardiovascular eventsSevere atopic dermatitisTreatment of adultsExposure-adjusted rates
2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
Silk AW, Barker CA, Bhatia S, Bollin KB, Chandra S, Eroglu Z, Gastman BR, Kendra KL, Kluger H, Lipson EJ, Madden K, Miller DM, Nghiem P, Pavlick AC, Puzanov I, Rabinowits G, Ruiz ES, Sondak VK, Tavss EA, Tetzlaff MT, Brownell I. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer. Journal For ImmunoTherapy Of Cancer 2022, 10: e004434. PMID: 35902131, PMCID: PMC9341183, DOI: 10.1136/jitc-2021-004434.Peer-Reviewed Original ResearchConceptsNonmelanoma skin cancerClinical practice guidelinesImmune checkpoint inhibitorsCutaneous squamous cell carcinomaMerkel cell carcinomaBasal cell carcinomaCell carcinomaPractice guidelinesSkin cancerCancer clinical practice guidelinesCancer care professionalsManagement of toxicitiesSpecial patient populationsSquamous cell carcinomaImmunotherapy of cancerConsensus-based recommendationsOwn clinical experienceRoutine clinical useCheckpoint inhibitorsMetastatic diseasePatient selectionPatients' qualityImmunotherapeutic treatmentPatient populationAggressive subtypeSex Differences in Moderate to Severe Psoriasis: Analysis of the Psoriasis Longitudinal Assessment and Registry
Goldburg S, Chen R, Langholff W, Lafferty K, Gooderham M, de Jong E, Strober B. Sex Differences in Moderate to Severe Psoriasis: Analysis of the Psoriasis Longitudinal Assessment and Registry. Journal Of Psoriasis And Psoriatic Arthritis 2022, 7: 132-139. PMID: 39296535, PMCID: PMC11361528, DOI: 10.1177/24755303221099848.Peer-Reviewed Original ResearchPsoriasis Longitudinal AssessmentDisease characteristicsDermatology Life Quality Index scoresDisease severitySystemic therapy-naïve patientsLife Quality Index scoresLongitudinal assessmentPhysician global assessmentSystemic steroid therapyLifestyle risk factorsTherapy-naïve patientsNonmelanoma skin cancerObjective disease severityBody surface areaHistory of anxietyQuality Index scoresQuality of lifeChi-square testPsoriasis characteristicsSteroid therapySevere psoriasisTherapy-naïveDisease durationBiologic-naïvePatient characteristics
2020
National Patterns in Prescription Opioid Use and Misuse Among Cancer Survivors in the United States
Jairam V, Yang DX, Verma V, Yu JB, Park HS. National Patterns in Prescription Opioid Use and Misuse Among Cancer Survivors in the United States. JAMA Network Open 2020, 3: e2013605. PMID: 32804217, PMCID: PMC7431994, DOI: 10.1001/jamanetworkopen.2020.13605.Peer-Reviewed Original ResearchConceptsPrescription opioid usePrescription opioid misuseRecent cancer survivorsOpioid useCancer survivorsAdult cancer survivorsOpioid misuseUse disordersHigher prescription opioid useRecent cancer historyCancer-related painHistory of cancerPopulation-based studyNonmelanoma skin cancerDrug use disordersCross-sectional studyAlcohol use disorderLong-term misusePrescription opioidsCancer historyMAIN OUTCOMESkin cancerDrug useYounger ageCancerPatient Perspectives on the Use of Artificial Intelligence for Skin Cancer Screening
Nelson CA, Pérez-Chada LM, Creadore A, Li SJ, Lo K, Manjaly P, Pournamdari AB, Tkachenko E, Barbieri JS, Ko JM, Menon AV, Hartman RI, Mostaghimi A. Patient Perspectives on the Use of Artificial Intelligence for Skin Cancer Screening. JAMA Dermatology 2020, 156: 501-512. PMID: 32159733, PMCID: PMC7066525, DOI: 10.1001/jamadermatol.2019.5014.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedArtificial IntelligenceBiopsyEarly Detection of CancerFemaleGrounded TheoryHealth Services AccessibilityHumansInterviews as TopicMaleMass ScreeningMelanomaMiddle AgedObserver VariationPatient Acceptance of Health CarePhysician-Patient RelationsQualitative ResearchReproducibility of ResultsSkin NeoplasmsConceptsSkin cancer screeningCancer screeningSkin cancerPatient's perspectiveAccurate diagnosisDana-Farber Cancer InstituteGeneral dermatology clinicNonmelanoma skin cancerHistory of melanomaHealth care accessPhysician-patient relationshipMelanoma clinicDermatology clinicWomen's HospitalPatient anxietySkin lesionsMAIN OUTCOMECare accessCancer InstitutePatientsQualitative studyCancerHealth careClinicHospital
2018
Comprehensive long‐term safety of adalimumab from 18 clinical trials in adult patients with moderate‐to‐severe plaque psoriasis
Leonardi C, Papp K, Strober B, Thaçi D, Warren R, Tyring S, Arikan D, Karunaratne M, Valdecantos W. Comprehensive long‐term safety of adalimumab from 18 clinical trials in adult patients with moderate‐to‐severe plaque psoriasis. British Journal Of Dermatology 2018, 180: 76-85. PMID: 30169904, DOI: 10.1111/bjd.17084.Peer-Reviewed Original ResearchMeSH KeywordsAdalimumabAdultAnti-Inflammatory AgentsClinical Trials as TopicDatasets as TopicFemaleHeadacheHumansIncidenceInjections, SubcutaneousLong-Term CareMaleMiddle AgedNasopharyngitisNeoplasmsOpportunistic InfectionsPsoriasisSeverity of Illness IndexTime FactorsTuberculosisTumor Necrosis Factor-alphaConceptsNonmelanoma skin cancerStandardized incidence ratiosStandardized mortality ratioAdverse eventsLong-term safetyPlaque psoriasisClinical trialsIncidence rateIncidence of NMSCSevere chronic plaque psoriasisTreatment-emergent adverse eventsAE incidence ratesChronic plaque psoriasisCommon adverse eventsSevere plaque psoriasisNew safety signalsUpper respiratory infectionIncidence of malignancyAnalysis of patientsTumor necrosis factorHuman monoclonal antibodyAdalimumab doseAdalimumab exposureLast doseAdult patients
2017
Ent Instructions for Authors
Wang LS, Handorf EA, Ridge JA, Burtness BA, Lango MN, Mehra R, Liu JC, Galloway TJ. Ent Instructions for Authors. Ear, Nose & Throat Journal 2017, 96: 271-272. PMID: 28719713, PMCID: PMC7549076, DOI: 10.1177/014556131709600703.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overChemoradiotherapy, AdjuvantChi-Square DistributionCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesHumansKaplan-Meier EstimateLogistic ModelsLymph NodesMaleMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalPrognosisRadiotherapy, AdjuvantRetrospective StudiesSkin NeoplasmsConceptsNonmelanoma skin cancerProgression-free survivalConcurrent chemoradiationLymph nodesLocoregional controlOverall survivalSkin cancerLocalized skin cancerLymph node measurementLymph node positiveGrade 4 thrombocytopeniaPositive lymph nodesSingle tertiary centerKaplan-Meier methodAggressive clinical courseAdjuvant concurrent chemoradiationAdvanced nonmelanoma skin cancersChi-square testAdjuvant radiationAdjuvant therapyClinical courseLocal recurrenceNode positiveTertiary centerCRT patients
2015
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial
Coric V, Salloway S, van Dyck CH, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T, Pilcher G, Ferris S, Colby S, Kerselaers W, Dockens R, Soares H, Kaplita S, Luo F, Pachai C, Bracoud L, Mintun M, Grill JD, Marek K, Seibyl J, Cedarbaum JM, Albright C, Feldman HH, Berman RM. Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial. JAMA Neurology 2015, 72: 1324-1333. PMID: 26414022, DOI: 10.1001/jamaneurol.2015.0607.Peer-Reviewed Original ResearchConceptsNonmelanoma skin cancerObservational cohortProdromal Alzheimer's diseaseProdromal ADClinical trialsPositron emission tomographyAlzheimer's diseaseDiscontinuation ratesCSF biomarkersBiomarker criteriaTreatment phasePlacebo-controlled phase 2 clinical trialSkin cancerGastrointestinal tract adverse eventsKey clinical outcome measuresSerious adverse event ratesΓ-Secretase Inhibitor AvagacestatEmission tomographyPhase 2 clinical trialPotential disease-modifying agentsBrain atrophy ratesLow discontinuation rateAdverse event ratesDisease-modifying agentsGreater brain atrophyFast Absorbing Gut Suture versus Cyanoacrylate Tissue Adhesive in the Epidermal Closure of Linear Repairs Following Mohs Micrographic Surgery.
Kim J, Singh Maan H, Cool AJ, Hanlon AM, Leffell DJ. Fast Absorbing Gut Suture versus Cyanoacrylate Tissue Adhesive in the Epidermal Closure of Linear Repairs Following Mohs Micrographic Surgery. The Journal Of Clinical And Aesthetic Dermatology 2015, 8: 24-9. PMID: 25741400, PMCID: PMC4345930.Peer-Reviewed Original ResearchMohs micrographic surgeryMicrographic surgeryCyanoacrylate tissue adhesiveGut sutureCosmetic outcomeFacial woundsThree-month postoperative visitLinear repairEpidermal closureTopical adhesiveComparable aesthetic outcomesOverall cosmetic outcomeMajority of patientsSatisfactory surgical outcomesNonmelanoma skin cancerAdditional patient visitsTissue adhesiveClosure techniqueWound closure methodsWound closure techniquesPostoperative visitSurgical outcomesWound lengthHead studiesContralateral side
2013
Skin Surface, Dermis, and Wound Healing
Decker R, Strom E, Wilson L. Skin Surface, Dermis, and Wound Healing. Medical Radiology 2013, 205-226. DOI: 10.1007/978-3-540-75863-1_9.Peer-Reviewed Original ResearchCollagen vascular diseaseRadiation dermatitisTherapeutic radiationActive collagen vascular diseaseAcute radiation dermatitisCutaneous side effectsLarge retrospective studyNonmelanoma skin cancerWound healingPrevious radiation exposureStages of severitySite of originRadiation recallConcurrent chemoradiotherapyConcurrent therapyRelative contraindicationSystemic agentsRetrospective reviewCutaneous reactionsNoncutaneous malignancyFibrotic changesRetrospective studyInflammatory pathwaysBreast radiotherapyNeck cancer
2012
Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease
Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, Pilcher G, Colby S, Rollin L, Dockens R, Pachai C, Portelius E, Andreasson U, Blennow K, Soares H, Albright C, Feldman HH, Berman RM. Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease. JAMA Neurology 2012, 69: 1430-1440. PMID: 22892585, DOI: 10.1001/archneurol.2012.2194.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesAmyloid Precursor Protein SecretasesBody WeightDose-Response Relationship, DrugDouble-Blind MethodEnzyme InhibitorsFemaleHumansImmunoprecipitationInternational CooperationMagnetic Resonance ImagingMaleMass SpectrometryMiddle AgedNeuropsychological TestsOutcome Assessment, Health CareOxadiazolesPsychiatric Status Rating ScalesSulfonamidestau ProteinsTime FactorsConceptsPhase 2 studyModerate Alzheimer's diseaseAdverse eventsAlzheimer's diseaseDiscontinuation ratesDose groupPharmacodynamic effectsAlzheimer's Disease Assessment Scale-cognitive subscale scoresTreatment-emergent serious adverse eventsDouble-blind treatment phaseΓ-Secretase Inhibitor AvagacestatSerious adverse eventsLow discontinuation rateNonmelanoma skin cancerCognitive subscale scoresDose armBiomarker substudyMedian ageMulticenter trialAcceptable safetyCognitive worseningΕ4 carriersCommon reasonTreatment groupsTreatment phase
2011
A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis
Gordon K, Langley R, Gottlieb A, Papp K, Krueger G, Strober B, Williams D, Gu Y, Valdes J. A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis. Journal Of Investigative Dermatology 2011, 132: 304-314. PMID: 22011907, DOI: 10.1038/jid.2011.304.Peer-Reviewed Original ResearchConceptsPlacebo-treated patientsSevere psoriasisWeek 52Adverse eventsWeek 12Placebo-controlled phase III studyMajor adverse cardiovascular eventsPrevious phase II trialGlobal assessmentPlacebo-controlled periodAdverse cardiovascular eventsPhysician global assessmentPhase II trialPhase III studyNonmelanoma skin cancerNonresponder imputationPASI 75Vs. 4.5Cardiovascular eventsII trialIII studyPsoriasis AreaControlled TrialsIL-12/23Maintenance treatmentA new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: Creation and rationale for inclusion of tumor (T) characteristics
Farasat S, Yu S, Neel V, Nehal K, Lardaro T, Mihm M, Byrd D, Balch C, Califano J, Chuang A, Sharfman W, Shah J, Nghiem P, Otley C, Tufaro A, Johnson T, Sober A, Liégeois N. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: Creation and rationale for inclusion of tumor (T) characteristics. Journal Of The American Academy Of Dermatology 2011, 64: 1051-1059. PMID: 21255868, PMCID: PMC4659347, DOI: 10.1016/j.jaad.2010.08.033.Peer-Reviewed Original ResearchConceptsAmerican Joint Committee on CancerCutaneous squamous cell carcinomaAmerican Joint Committee on Cancer staging systemSquamous cell carcinomaStaging systemT classificationCell carcinomaStaging ManualAmerican Joint Committee on Cancer Staging ManualAmerican Joint Committee on Cancer Cancer Staging ManualIncidence of cutaneous squamous cell carcinomaMultivariate analysisPurposes of stagingCancer staging systemHigh-risk featuresCancer Staging ManualNonmelanoma skin cancerProspective outcome trialsTumor thicknessTumor characteristicsTumor diameterPerineural invasionAdvanced diseaseSurgical treatmentStaging criteria
2007
Management of nonmelanoma skin cancer in 2007
Neville JA, Welch E, Leffell DJ. Management of nonmelanoma skin cancer in 2007. Nature Reviews Clinical Oncology 2007, 4: 462-469. PMID: 17657251, DOI: 10.1038/ncponc0883.Peer-Reviewed Original ResearchConceptsNonmelanoma skin cancerSkin cancerNew noninvasive treatmentImmune response modifiersMohs micrographic surgeryTopical chemotherapeuticsSelect tumorsHistological patternMicrographic surgerySurgical methodsConventional excisionNoninvasive optionNoninvasive treatmentTumor typesSurgeryCancerPhotodynamic therapyTreatmentCurettageMorbidityElectrodesiccationTherapyTumorsExcisionRetinoidsRisk of Second Cancer in Nongastric Marginal Zone B-Cell Lymphomas of Mucosa-Associated Lymphoid Tissue: A Population-Based Study from Northern Italy
Arcaini L, Burcheri S, Rossi A, Pascutto C, Passamonti F, Brusamolino E, Paulli M, Orlandi E, Buelli M, Viero P, Lucioni M, Montanari F, Merli M, Cortelazzo S, Lazzarino M. Risk of Second Cancer in Nongastric Marginal Zone B-Cell Lymphomas of Mucosa-Associated Lymphoid Tissue: A Population-Based Study from Northern Italy. Clinical Cancer Research 2007, 13: 182-186. PMID: 17200353, DOI: 10.1158/1078-0432.ccr-06-0703.Peer-Reviewed Original ResearchConceptsStandardized incidence ratiosMarginal zone B-cell lymphomaIncidence ratiosSecond cancersB-cell lymphomaLymphoid tissueGeneral populationSolid tumorsSkin cancerMucosa associated lymphoid tissueSex-specific incidence ratesSite of cancerNonmelanoma skin cancerMarginal zone lymphomaSitu skin cancersNongastric MALT lymphomasExtranodal sitesAdditional malignanciesPrevious malignancyCancer RegistryComparison of risksSecond tumorMALT lymphomaIncidence rateHematologic diseases
2005
PTCH codon 1315 polymorphism and risk for nonmelanoma skin cancer
Asplund A, Gustafsson AC, Wikonkal NM, Sela A, Leffell DJ, Kidd K, Lundeberg J, Brash DE, Pontén F. PTCH codon 1315 polymorphism and risk for nonmelanoma skin cancer. British Journal Of Dermatology 2005, 152: 868-873. PMID: 15888139, DOI: 10.1111/j.1365-2133.2005.06464.x.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Basal CellCarcinoma, Squamous CellCodonGenetic Predisposition to DiseaseGenotypeHair ColorHumansLoss of HeterozygosityNeoplasm ProteinsPatched ReceptorsPatched-1 ReceptorPilot ProjectsPolymerase Chain ReactionPolymorphism, Single NucleotideReceptors, Cell SurfaceSkin NeoplasmsSkin PigmentationConceptsPro/Pro genotypeNonmelanoma skin cancerBasal cell carcinomaPTCH tumor suppressor geneSquamous cell carcinomaAllele frequency variationAllelic loss studiesTumor suppressor genePro genotypeSingle nucleotide polymorphismsAllelic lossGenomic DNANonrandom lossSuppressor geneCell carcinomaSwedish patientsEpithelial cell cancersLight pigmentationSkin cancerNucleotide polymorphismsMultiple basal cell carcinomasPro/LeuHuman populationPTCH geneAllele frequencies
2001
The Melanocortin-1 Receptor: Red Hair and Beyond
Schaffer J, Bolognia J. The Melanocortin-1 Receptor: Red Hair and Beyond. JAMA Dermatology 2001, 137: 1477-1485. PMID: 11708951, DOI: 10.1001/archderm.137.11.1477.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMelanocortin 1 receptorTransmembrane-spanning domainsG protein-coupled receptorsProtein-coupled receptorsRed hair phenotypeHuman pigmentationPigmentation phenotypesHair phenotypePheomelanin synthesisRed hairType of melaninHeterozygote effectUV-induced melanogenesisNonmelanoma skin cancerPhenotypeDecreased abilityReceptorsKey roleMelanocortin receptorsSkin cancerLociGeneticsFair skinPhysiologic variationsVariants
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply